As of 2026-02-04, the Relative Valuation of Neovacs SA (ALNEV.PA) is (158.34) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 0.00 EUR, the upside of Neovacs SA based on Relative Valuation is -5278122.1%.
The range of the Relative Valuation is (183.72) - (112.48) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 9.5x - 15.4x | 11.9x |
| Forward P/E multiples | 25.1x - 31.8x | 31.4x |
| Fair Price | (183.72) - (112.48) | (158.34) |
| Upside | -6124068.4% - -3749567.9% | -5278122.1% |
| Date | P/E |
| 2026-01-23 | -0.00 |
| 2026-01-22 | -0.00 |
| 2026-01-21 | -0.00 |
| 2026-01-20 | -0.00 |
| 2026-01-19 | -0.00 |
| 2026-01-16 | -0.00 |
| 2026-01-15 | -0.00 |
| 2026-01-14 | -0.00 |
| 2026-01-13 | -0.00 |
| 2026-01-12 | -0.00 |
| 2026-01-09 | -0.00 |
| 2026-01-08 | -0.00 |
| 2026-01-07 | -0.00 |
| 2026-01-06 | -0.00 |
| 2026-01-05 | -0.00 |
| 2026-01-02 | -0.00 |
| 2025-12-31 | -0.00 |
| 2025-12-30 | -0.00 |
| 2025-12-29 | -0.00 |
| 2025-12-24 | -0.00 |
| 2025-12-23 | -0.00 |
| 2025-12-22 | -0.00 |
| 2025-12-19 | -0.00 |
| 2025-12-18 | -0.00 |
| 2025-12-17 | -0.00 |
| 2025-12-16 | -0.00 |
| 2025-12-15 | -0.00 |
| 2025-12-12 | -0.00 |
| 2025-12-11 | -0.00 |
| 2025-12-10 | -0.00 |
| 2025-12-09 | -0.00 |
| 2025-12-08 | -0.00 |
| 2025-12-05 | -0.00 |
| 2025-12-04 | -0.00 |
| 2025-12-03 | -0.00 |
| 2025-12-02 | -0.00 |
| 2025-12-01 | -0.00 |
| 2025-11-28 | -0.00 |
| 2025-11-27 | -0.00 |
| 2025-11-26 | -0.00 |
| 2025-11-25 | -0.00 |
| 2025-11-24 | -0.00 |
| 2025-11-21 | -0.00 |
| 2025-11-20 | -0.00 |
| 2025-11-19 | -0.00 |
| 2025-11-18 | -0.00 |
| 2025-11-17 | -0.00 |
| 2025-11-14 | -0.00 |
| 2025-11-13 | -0.00 |
| 2025-11-12 | -0.00 |